Benzinga | Aug 9, 2021 04:20PM EDT

Arcturus Therapeutics Q2 EPS $(2.07) Beats $(2.14) Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of $(2.14) by 3.27 percent. This is a 276.36 percent decrease over losses of $(0.55) per share from the same period last year.